TIDMTSP
RNS Number : 4251N
TruSpine Technologies PLC
31 May 2022
31 May 2022
TruSpine Technologies plc
("TruSpine" or the "Company")
Fundraise, Issue of Warrants & Appointment of Broker and
Financial Adviser
TruSpine Technologies plc, (AQSE: TSP) the medical device
company focused on the development of its pioneering "screwless"
spinal (vertebral) stabilisation systems announces that it
has:-
- raised in aggregate GBP 700,000 as part of a fundraise through
the issue of 14,000,000 new ordinary shares at a price of 5 pence
per share. Oberon Capital and Peterhouse Capital acted as joint
brokers to the Fundraise;
- the settlement of GBP77,500 of third-party creditors through
the issue of 1,550,000 new ordinary shares at a price of 5 pence
per share ("Settlement Shares");
- issued 15,550,000 warrants over new ordinary shares in the
Company exercisable at a price of 7.5 pence per share to
participants in the placing, subscription and in relation to
Settlement Shares;
- agreed the conversion of GBP97,200 accrued director fees into
648,000 new ordinary shares at a price of 15 pence per share;
and
- appointed Peterhouse Capital Limited ("Peterhouse") as joint
broker and Financial Adviser to the Company.
Fundraise & Issue of Warrants
The fundraise comprises a placing and subscription at a price of
5 pence per ordinary shares ("Fundraise").
- 10,800,000 new ordinary shares will be issued by way of a
placing, raising gross proceeds of GBP540,000 (the "Placing")
and
- 3,200,000 new ordinary shares will be issued by way of a
subscription, raising gross proceeds of GBP160,000 (the
"Subscription").
An additional 1,550,000 shares will be issued at a price of 5
pence per ordinary share to third-party creditors of GBP77,500 in
lieu of services rendered ("Settlement Shares").
Each Placing share, Subscription share and Settlement Share
issued has a warrant attached allowing the holder to subscribe for
1 additional share in the Company at an exercise price of 7.5 pence
for a period of 3 years from Admission (the "New Warrant"). New
Warrants have been issued over 15,550,000 new ordinary shares.
The net proceeds of the Fundraise will be utilised to complete
the final validation and verification of packaging and
instrumentation prior to the FDA 510k lodgement and ongoing working
capital through FDA clearance process.
Fee Shares and Director Participation
Accrued director fees of GBP97,200 will be settled through the
issue of 648,000 new ordinary shares at a price of 15 pence per
share ("Fee Shares").
Norman Lott, Chief Financial Officer of the Company and Nikunj
Patel, Non-Executive Director of the Company, are participating in
the Fundraise. Details of their participation are set out in the
table below along with the revised shareholdings of the Directors
following the issue of Fee Shares.
Director Current Fee Shares Subscription Resultant Resultant
Shares shares shareholding percentage
following shareholding
Admission following
Admission
Ian Roberts
(CEO) 861,111 Nil Nil 861,111 0.7%
-------------------------- ---------------------------- ------------- ---------------------------------------- -------------
Norman Lott
(CFO) 1,750,000 Nil 200,000 1,950,000 1.7%
-------------------------- ---------------------------- ------------- ---------------------------------------- -------------
Martin
Armstrong
(Chairman) 333,333 408,000 Nil 741,333 0.6%
-------------------------- ---------------------------- ------------- ---------------------------------------- -------------
Annabel
Schild
(NED) 4,166,667 80,000 Nil 4,246,667 3.6%
-------------------------- ---------------------------- ------------- ---------------------------------------- -------------
Dr Tim
Evans
(NED) 166,667 80,000 Nil 246,667 0.2%
-------------------------- ---------------------------- ------------- ---------------------------------------- -------------
Nikunj
Patel
(NED) 250,000 80,000 1,000,000 1,330,000 1.1%
-------------------------- ---------------------------- ------------- ---------------------------------------- -------------
Total 7,527,778 648,000 1,200,000 9,375,778 7.9%
-------------------------- ---------------------------- ------------- ---------------------------------------- -------------
724,902 new ordinary shares ("Historical Shares") were issued by
the Company between October and November 2021 to settle third-party
outstanding liabilities of GBP69,760. Due to an administrative
oversight by the Company, no announcement or application was made
for these shares to be admitted to trading on the AQSE Market.
Admisssion of Shares
In aggregate application has been made for 16,922,902 new
ordinary shares to be admitted to trading on AQSE which is expected
to occur on or around 8 June 2022 ("Admission")
Appointment of Joint Broker and Financial Adviser
The Company announces that it has appointed Peterhouse Capital
Limited as joint broker and financial adviser to the Company with
immediate effect.
Broker Warrants
As part of their renumeration Oberon and Peterhouse have been
granted warrants over 540,000 new ordinary shares exercisable at a
price of 5 pence per share at any time until third anniversary of
Admission.
Total Voting Rights
Following Admission of the 16,922,902 new ordinary shares, the
Company's issued share capital will consist of 118,311,869
(including the 724,902 ordinary shares issued but not admitted to
trading on AQSE previously) ordinary shares with voting rights. The
new ordinary shares will rank pari passu with the existing ordinary
shares. No ordinary shares are held in treasury at the date of this
announcement and therefore following the Admission, the total
number of Ordinary Shares in the Company with voting rights will be
118,311,869.
The above total voting rights figure may be used by shareholders
as the denominator for the calculation by which they will determine
if they are required to notify their interest in, or a change to
their interest in the Company.
Ian Roberts, CEO of TruSpine, commented: "This fundraise will
take us to the next stage of development as we look towards
completing the final validation and verification of packaging and
instrumentation of Cervi-LOK(TM). This is a critical phase leading
up to lodgement of the FDA 510k application and we look forward to
what we hope will be a rapid move towards commercialisation later
this year."
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation and the Directors of the Company
are responsible for the release of this announcement.
Enquiries:
TruSpine Technologies Plc Tel: +44 (0)20 3638 5025
Ian Roberts, CEO
Cairn Financial Advisers LLP (AQSE Corporate Tel: +44 (0)20
Adviser) 7213 0880
Liam Murray / Ludovico Lazzaretti
Oberon Capital (Joint Broker) Tel: +44 (0)20 3179 5300
Mike Seabrook / Chris Crawford
Peterhouse Capital Limited (Joint Broker
& Financial Adviser)
Lucy Williams / Duncan Vasey Tel: +44 (0)20 7469 0930
Walbrook PR (Financial Tel: +44 (0) 20 7933 7870 or +44 (0)
PR & IR) 7876 741 001
Anna Dunphy truspine@walbrookpr.com
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------------------------------------------------------------------------------------------
a. Name 1) Martin Armstrong
2) Annabel Schild
3) Dr Tim Evans
4) Nikunj Patel
--------------------------------- -------------------------------------------------------
2 Reason for notification
--------------------------------- -------------------------------------------------------
a. Position/Status PDMR
1) Chairman
2) NED
3) NED
4) NED
--------------------------------- -------------------------------------------------------
b. Initial notification/ Initial notification
Amendment
--------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------
a. Name TruSpine Technologies Plc
--------------------------------- -------------------------------------------------------
b. LEI 213800HNZX9B1QZPB225
--------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------------------------
a. Description of Ordinary shares of 0.01 pence each
the financial
instrument, type
of instrument
ISIN: GB00BMZCKL55
Identification
Code
--------------------------------- -------------------------------------------------------
b. Nature of the Issue of ordinary shares in lieu of director
transaction fees
--------------------------------- -------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
--------------------------------- ----- -----------------------
1) GBP0.15 1) 408,000
2) GBP0.15 2) 80,000
3) GBP0.15 3) 80,000
4) GBP0.15 4) 80,000
--------------------------------------------------------------------- -------------------
d. Aggregated information
* Volume N/A
* Price
--------------------------------- -------------------------------------------------------
e. Date of the transaction 8 June 2022
--------------------------------- -------------------------------------------------------
f. Place of the transaction London
--------------------------------- -------------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------------------------------------------------------------------------------------------------
a. Name 1) Norman Lott
2) Nikunj Patel
------------------------------- ---------------------------------------------------------------
2 Reason for notification
------------------------------- ---------------------------------------------------------------
a. Position/Status PDMR
1) CFO
2) NED
------------------------------- ---------------------------------------------------------------
b. Initial notification/ Initial notification
Amendment
------------------------------- ---------------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------------
a. Name TruSpine Technologies Plc
------------------------------- ---------------------------------------------------------------
b. LEI 213800HNZX9B1QZPB225
------------------------------- ---------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------------------------------
a. Description of Ordinary shares of 0.01 pence each
the financial
instrument, type
of instrument
ISIN: GB00BMZCKL55
Identification
Code
------------------------------- ---------------------------------------------------------------
b. Nature of the Purchase of ordinary shares through the Subscription
transaction
------------------------------- ---------------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------- ------ ------------------------
1) GBP0.05 1) 200,000
2) GBP0.05 2) 1,000,000
--------------------------------------------------------------------- -------------------------
d. Aggregated information
* Volume N/A
* Price
------------------------------- ---------------------------------------------------------------
e. Date of the transaction 8 June 2022
------------------------------- ---------------------------------------------------------------
f. Place of the transaction London
------------------------------- ---------------------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
--------------------------------------------------------------------------------------
a. Name 1) Norman Lott
2) Nikunj Patel
------------------------------ ------------------------------------------------------
2 Reason for notification
------------------------------ ------------------------------------------------------
a. Position/Status PDMR
1) CFO
2) NED
------------------------------ ------------------------------------------------------
b. Initial notification/ Initial notification
Amendment
------------------------------ ------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------
a. Name TruSpine Technologies Plc
------------------------------ ------------------------------------------------------
b. LEI 213800HNZX9B1QZPB225
------------------------------ ------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--------------------------------------------------------------------------------------
a. Description of Warrants over ordinary shares of 0.01 pence
the financial each
instrument, type
of instrument
Identification ISIN: GB00BMZCKL55
Code
------------------------------ ------------------------------------------------------
b. Nature of the Issue of Warrants
transaction
------------------------------ ------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------ ----- ---------------------
1) GBP0.075 1) 200,000
2) GBP0.075 2) 1,000,000
--------------------------------------------------------------- --------------------
d. Aggregated information
* Volume N/A
* Price
------------------------------ ------------------------------------------------------
e. Date of the transaction 8 June 2022
------------------------------ ------------------------------------------------------
f. Place of the transaction London
------------------------------ ------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXFFLFXLELXBBZ
(END) Dow Jones Newswires
May 31, 2022 07:45 ET (11:45 GMT)
TruSpine Technologies (AQSE:TSP)
Historical Stock Chart
From Dec 2024 to Jan 2025
TruSpine Technologies (AQSE:TSP)
Historical Stock Chart
From Jan 2024 to Jan 2025